$6.91
0.07% today
Nasdaq, Feb 05, 04:20 pm CET
ISIN
US00437E1029
Symbol
ACCD
Sector
Industry

Accolade Stock price

$6.91
+3.41 97.43% 1M
+3.27 89.84% 6M
+3.49 102.05% YTD
-4.95 41.74% 1Y
-12.58 64.55% 3Y
-22.79 76.73% 5Y
-22.79 76.73% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-0.03 0.43%
ISIN
US00437E1029
Symbol
ACCD
Sector
Industry

Key metrics

Market capitalization $564.40m
Enterprise Value $576.81m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.29
P/S ratio (TTM) P/S ratio 1.26
P/B ratio (TTM) P/B ratio 1.79
Revenue growth (TTM) Revenue growth 14.99%
Revenue (TTM) Revenue $446.72m
EBIT (operating result TTM) EBIT $-85.98m
Free Cash Flow (TTM) Free Cash Flow $-12.74m
Cash position $225.48m
EPS (TTM) EPS $-2.25
P/E forward negative
P/S forward 1.21
EV/Sales forward 1.24
Short interest 3.97%
Show more

Is Accolade a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Accolade Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Accolade forecast:

2x Buy
17%
10x Hold
83%

Analyst Opinions

12 Analysts have issued a Accolade forecast:

Buy
17%
Hold
83%

Financial data from Accolade

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Nov '24
+/-
%
447 447
15% 15%
100%
- Direct Costs 275 275
6% 6%
62%
172 172
33% 33%
38%
- Selling and Administrative Expenses 122 122
3% 3%
27%
- Research and Development Expense 92 92
6% 6%
21%
-42 -42
51% 51%
-9%
- Depreciation and Amortization 44 44
4% 4%
10%
EBIT (Operating Income) EBIT -86 -86
35% 35%
-19%
Net Profit -180 -180
47% 47%
-40%

In millions USD.

Don't miss a Thing! We will send you all news about Accolade directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Accolade Stock News

Neutral
PRNewsWire
one day ago
Effort broadens healthcare access and removes barriers to primary care and weight management services SEATTLE , Feb. 4, 2025 /PRNewswire/ -- Today, Accolade, Inc. (NASDAQ: ACCD) announced that its direct-to-consumer virtual healthcare offering, PlushCare, is now accepting Medicare Part B, expanding care access to 64 million beneficiaries across all 50 states. PlushCare offers quality primary ca...
Neutral
PRNewsWire
26 days ago
NEW YORK , Jan. 10, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Accolade (NASDAQ: ACCD) and its board of directors concerning the proposed acquisition of the company by Transcarent. Stockholders will receive $7.03 for each share of Accolade stock that they hold.
Neutral
Business Wire
28 days ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Accolade, Inc. (NasdaqGS: ACCD) to Transcarent. Under the terms of the proposed transaction, shareholders of Accolade will receive $7.03 in cash for each share of Accolade that they own. KSF is seeking to determin...
More Accolade News

Company Profile

Accolade, Inc. is an emerging growth company, which engages in the provision of personalized, technology-enabled solutions through a technology platform. It offers Accolade Total Benefits and Accolade Total Care. Accolade Total Benefits focuses on member benefits engagement and Accolade Total Care help guides members to healthcare providers. The company was founded by Thomas K. Spann and J. Michael Cline in 2007 and is headquartered in Seattle, WA.

Head office United States
CEO Rajeev Singh
Employees 2,400
Founded 2007
Website www.accolade.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today